Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy



Status:Completed
Conditions:High Cholesterol
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:18 - Any
Updated:4/21/2016
Start Date:July 2012
End Date:December 2014

Use our guide to learn which trials are right for you!

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy

Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that binds PCSK9
(proprotein convertase subtilisin/kexin type 9).

Primary Objective of the study:

To evaluate the effect of alirocumab on low-density lipoprotein cholesterol (LDL-C) levels
after 24 weeks of treatment in comparison with placebo.

Secondary Objectives:

- To evaluate the effect of alirocumab in comparison with placebo on LDL-C at other time
points

- To evaluate the effects of alirocumab on other lipid parameters

- To evaluate the safety and tolerability of alirocumab

The maximum study duration was planned to be 89 weeks per participant including participants
who successfully completed the 78-week treatment period had the possibility to join an
open-label extension study (LTS13463, NCT01954394) at the end of the treatment period.

Inclusion criteria:

- Participants with heterozygous familial hypercholesterolemia who were not adequately
controlled with their lipid-modifying therapy

Exclusion criteria:

- Age < 18 years or legal age of adulthood, whichever is greater

- LDL-C < 70 mg/dL (1.81 mmol/L) and with cardiovascular disease

- LDL-C < 100 mg/dL (2.59 mmol/L) and without cardiovascular disease

- Fasting serum triglycerides > 400 mg/dL (4.52 mmol/L)

- Known history of homozygous familial hypercholesterolemia

The above information is not intended to contain all considerations relevant to a
participant's potential participation in a clinical trial.
We found this trial at
25
sites
?
mi
from
Portland, OR
Click here to add this to my saved trials
?
mi
from
Auburn, ME
Click here to add this to my saved trials
?
mi
from
Bell Gardens, CA
Click here to add this to my saved trials
?
mi
from
Boston, MA
Click here to add this to my saved trials
?
mi
from
Bountiful, UT
Click here to add this to my saved trials
Charlotte, North Carolina 28207
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
?
mi
from
Dallas, TX
Click here to add this to my saved trials
?
mi
from
Durham, NC
Click here to add this to my saved trials
?
mi
from
Evanston, IL
Click here to add this to my saved trials
?
mi
from
Graz,
Click here to add this to my saved trials
?
mi
from
Kansas City, KS
Click here to add this to my saved trials
?
mi
from
Long Beach, CA
Click here to add this to my saved trials
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
?
mi
from
Miami, FL
Click here to add this to my saved trials
Mission Viejo, California 92691
?
mi
from
Mission Viejo, CA
Click here to add this to my saved trials
?
mi
from
Morristown, NJ
Click here to add this to my saved trials
?
mi
from
Nashville, TN
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
Newport Beach, California 92660
?
mi
from
Newport Beach, CA
Click here to add this to my saved trials
?
mi
from
Northridge, CA
Click here to add this to my saved trials
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
?
mi
from
Ponte Vedra, FL
Click here to add this to my saved trials
?
mi
from
St Louis, MO
Click here to add this to my saved trials
?
mi
from
Washington,
Click here to add this to my saved trials